MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rena, G.
Right arrow Articles by Houslay, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rena, G.
Right arrow Articles by Houslay, M. D.

Vol. 59, Issue 5, 996-1011, May 2001

Molecular Cloning, Genomic Positioning, Promoter Identification, and Characterization of the Novel Cyclic AMP-Specific Phosphodiesterase PDE4A10

Graham Rena,1 Fiona Begg,2 Annette Ross,3 Carolynn MacKenzie, Ian McPhee,4 Lachlan Campbell, Elaine Huston, Michael Sullivan,5 and Miles D. Houslay

Molecular Pharmacology Group, Division of Biochemistry and Molecular Biology, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom

We describe the cloning and expression of HSPDE4A10, a novel long form splice variant of the human cAMP phosphodiesterase PDE4A gene. The 825 amino acid HSPDE4A10 contains a unique N terminus of 46 amino acids encoded by a unique 5' exon. Exon-14A10 lies ~11 kilobase pairs (kb) downstream of exon-14A4 and ~13.5 kb upstream of the PDE4A common exon 2. We identify a rat PDE4A10 ortholog and reveal a murine ortholog by nucleotide sequence database searching. PDE4A10 transcripts were detected in various human cell lines and tissues. The 5' sequence flanking exon-14A10 exhibited promoter activity with the minimal functional promoter region being highly conserved in the corresponding mouse genomic sequence. Transient expression of the engineered human PDE4A10 open reading frame in COS7 cells allowed detection of a 121-kDa protein in both soluble and particulate fractions. PDE4A10 was localized primarily to the perinuclear region of COS7 cells. Soluble and particulate forms exhibited similar Km values for cAMP hydrolysis (3-4 µM) and IC50 values for inhibition by rolipram (50 nM) but the Vmax value of the soluble form was ~3-fold greater than that of the particulate form. At 55°C, soluble HSPDE4A10 was more thermostable (T0.5 = 11 min) than the particulate enzyme (T0.5 = 5 min). HSPDE4A10 and HSPDE4A4B are shown here to be similar in size and exhibit similar maximal activities but differ with respect to sensitivity to inhibition by rolipram, thermostability, interaction with the SRC homology 3 domain of LYN, an SRC family tyrosyl kinase, and subcellular localization. We suggest that the unique N-terminal regions of PDE4A isoforms confer distinct properties upon them.

1 Current address: MRC Protein Phosphorylation Unit, Department of Biochemistry, University of Dundee, Dundee DD1 5EH, Scotland.

2 Current address: Grant Management, 20-23 Woodside Place, Glasgow G3 7QF, Scotland, UK.

3 Current address: Department of Botany, University of Cambridge, Cambridge, CB12 1QW, England, UK.

4 Current address: Scottish Biomedical, Block H, Ground Floor, Telford Pavilion, Todd Campus West of Scotland Science Park, Glasgow G20 0XA, Scotland, UK.

5 Current address: AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leicestershire, LE11 5RH, England, UK.

Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
Y.-F. Cheung, Z. Kan, P. Garrett-Engele, I. Gall, H. Murdoch, G. S. Baillie, L. M. Camargo, J. M. Johnson, M. D. Houslay, and J. C. Castle
PDE4B5, a Novel, Super-Short, Brain-Specific cAMP Phosphodiesterase-4 Variant Whose Isoform-Specifying N-Terminal Region Is Identical to That of cAMP Phosphodiesterase-4D6 (PDE4D6)
J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 600 - 609.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
M. D. Houslay, G. S. Baillie, and D. H. Maurice
cAMP-Specific Phosphodiesterase-4 Enzymes in the Cardiovascular System: A Molecular Toolbox for Generating Compartmentalized cAMP Signaling
Circ. Res., April 13, 2007; 100(7): 950 - 966.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
K. Omori and J. Kotera
Overview of PDEs and Their Regulation
Circ. Res., February 16, 2007; 100(3): 309 - 327.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
E. Stefan, B. Wiesner, G. S. Baillie, R. Mollajew, V. Henn, D. Lorenz, J. Furkert, K. Santamaria, P. Nedvetsky, C. Hundsrucker, et al.
Compartmentalization of cAMP-Dependent Signaling by Phosphodiesterase-4D Is Involved in the Regulation of Vasopressin-Mediated Water Reabsorption in Renal Principal Cells
J. Am. Soc. Nephrol., January 1, 2007; 18(1): 199 - 212.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
A. T. Bender and J. A. Beavo
Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use
Pharmacol. Rev., September 1, 2006; 58(3): 488 - 520.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
D. G. Tilley and D. H. Maurice
Vascular Smooth Muscle Cell Phenotype-Dependent Phosphodiesterase 4D Short Form Expression: Role of Differential Histone Acetylation on cAMP-Regulated Function
Mol. Pharmacol., September 1, 2005; 68(3): 596 - 605.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. D. Houslay
The Long and Short of Vascular Smooth Muscle Phosphodiesterase-4 As a Putative Therapeutic Target
Mol. Pharmacol., September 1, 2005; 68(3): 563 - 567.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
D. A. Wallace, L. A. Johnston, E. Huston, D. MacMaster, T. M. Houslay, Y.-F. Cheung, L. Campbell, J. E. Millen, R. A. Smith, I. Gall, et al.
Identification and Characterization of PDE4A11, a Novel, Widely Expressed Long Isoform Encoded by the Human PDE4A cAMP Phosphodiesterase Gene
Mol. Pharmacol., June 1, 2005; 67(6): 1920 - 1934.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. B. Bolger, A. H. Peden, M. R. Steele, C. MacKenzie, D. G. McEwan, D. A. Wallace, E. Huston, G. S. Baillie, and M. D. Houslay
Attenuation of the Activity of the cAMP-specific Phosphodiesterase PDE4A5 by Interaction with the Immunophilin XAP2
J. Biol. Chem., August 29, 2003; 278(35): 33351 - 33363.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. R. Le Jeune, M. Shepherd, G. Van Heeke, M. D. Houslay, and I. P. Hall
Cyclic AMP-dependent Transcriptional Up-regulation of Phosphodiesterase 4D5 in Human Airway Smooth Muscle Cells. IDENTIFICATION AND CHARACTERIZATION OF A NOVEL PDE4D5 PROMOTER
J. Biol. Chem., September 20, 2002; 277(39): 35980 - 35989.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. V. Donadio and J. P. Grande
IgA Nephropathy
N. Engl. J. Med., September 5, 2002; 347(10): 738 - 748.
[Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
G. Baillie, S. J. MacKenzie, and M. D. Houslay
Phorbol 12-myristate 13-acetate Triggers the Protein Kinase A-Mediated Phosphorylation and Activation of the PDE4D5 cAMP Phosphodiesterase in Human Aortic Smooth Muscle Cells through a Route Involving Extracellular Signal Regulated Kinase (ERK)
Mol. Pharmacol., November 1, 2001; 60(5): 1100 - 1111.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics